Harbor Capital Advisors’s Freeline Therapeutics Holdings FRLN Stock Holding History
Bought
Maintained
Sold
Harbor Capital Advisors's FRLN Position: Q1 2024 in Review
Harbor Capital Advisors sold out of Freeline Therapeutics Holdings (FRLN) in Q1 2024, closing a stake of 20,352 shares — an estimated $129K sold.
Harbor Capital Advisors first reported a position in FRLN in Q4 2021 and held it in 9 quarters. The position peaked at $360K in Q4 2021. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.
- Harbor Capital Advisors reported no remaining Freeline Therapeutics Holdings position as of Q1 2024 after selling out during the quarter.
- Harbor Capital Advisors sold 20,352 Freeline Therapeutics Holdings shares in Q1 2024, an estimated $129K.
- Harbor Capital Advisors first reported a position in Freeline Therapeutics Holdings in Q4 2021 and held it in 9 quarters.
- Harbor Capital Advisors's Freeline Therapeutics Holdings position peaked at $360K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q1 2024.
Based on Harbor Capital Advisors's 13F filing for Q1 2024, filed 13 May 2024.